tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
AnaptysBio announces $100M share repurchase program
PremiumThe FlyAnaptysBio announces $100M share repurchase program
2d ago
GSK subsidiary initiates litigation against AnaptysBio
Premium
The Fly
GSK subsidiary initiates litigation against AnaptysBio
3d ago
AnaptysBio price target lowered to $52 from $59 at H.C. Wainwright
Premium
The Fly
AnaptysBio price target lowered to $52 from $59 at H.C. Wainwright
12d ago
AnaptysBio: Phase 2 rosnilimab trial did not meet primary, secondary endpoints
PremiumThe FlyAnaptysBio: Phase 2 rosnilimab trial did not meet primary, secondary endpoints
13d ago
AnaptysBio trading halted, news pending
Premium
The Fly
AnaptysBio trading halted, news pending
13d ago
AnaptysBio’s Strategic Split and Robust Pipeline Justify Buy Rating
Premium
Ratings
AnaptysBio’s Strategic Split and Robust Pipeline Justify Buy Rating
18d ago
AnaptysBio price target raised to $80 from $55 at Stifel
PremiumThe FlyAnaptysBio price target raised to $80 from $55 at Stifel
25d ago
AnaptysBio price target raised to $70 from $45 at Wedbush
Premium
The Fly
AnaptysBio price target raised to $70 from $45 at Wedbush
1M ago
Positive Outlook for AnaptysBio: Strategic Developments and Promising Trial Results Drive Buy Rating
Premium
Ratings
Positive Outlook for AnaptysBio: Strategic Developments and Promising Trial Results Drive Buy Rating
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100